Sight Sciences Announces Medicare Fee Schedule for TearCare Procedure, Enhancing Access to Interventional Dry Eye Treatment
MENLO PARK, Calif., Oct. 17, 2025’ Sight Sciences, Inc. (Nasdaq: SGHT), a pioneering eyecare technology company dedicated to revolutionizing the treatment landscape for eye-related conditions, has made significant strides in patient care by announcing the establishment of a fee schedule for its innovative TearCare® System. This move follows the decision by two key Medicare Administrative Contractors (MACs), Novitas Solutions, Inc. and First Coast Service Options, Inc. (FCSO), to set jurisdiction-wide pricing for the popular procedure aimed at treating dry eye syndrome.
The procedure, identified by the CPT code 0563T, encompasses the evacuation of meibomian glands using heat delivered through wearable, open-eye eyelid treatment devices in conjunction with manual expression termed bilateral treatment. This eligibility for reimbursement marks a substantial advancement, as it enhances the accessibility of a unique treatment modality for patients suffering from chronic dry eye, a condition impacting millions across the United States.
The approved Medicare fee schedule will be effective for services rendered on or after January 1, 2025, in all jurisdictions and localities governed by Novitas and FCSO. This inclusion signifies a momentous endorsement from Medicare and reflects the growing recognition of TearCare as a validated therapeutic option for patients, paving the way for wider utilization in clinical practice.
Sight Sciences’ innovative TearCare System addresses a critical gap in dry eye management by utilizing a technology platform that combines proprietary warm, compressive, and mechanical therapies aimed at promoting the natural function of the meibomian glands. Dry eye syndrome can significantly degrade patients’ quality of life, presenting symptoms such as discomfort, visual disturbances, and even potential damage to the ocular surface. The ability to perform the 0563T procedure as a reimbursable option significantly broadens treatment avenues for ophthalmologists and optometrists alike, facilitating enhanced patient quality and outcomes.
“Achieving a fee schedule for our TearCare procedure is a critical milestone for Sight Sciences and emphasizes our commitment to advancing the care and treatment options available for individuals with dry eye disease,” said a spokesperson from Sight Sciences. “With the endorsement by Novitas and FCSO, we are one step closer to allowing both healthcare providers and patients to conveniently access this much-needed intervention.”
The proactive collaboration between Sight Sciences and Medicare contractors spotlights a growing awareness around dry eye syndrome and the necessity for effective, reimbursable treatment options. The establishment of the fee schedule aligns with broader trends in healthcare toward the integration of innovative therapies that prioritize patient welfare and clinical efficiency.
As the healthcare industry recalibrates to accommodate novel treatments, Sight Sciences stands at the forefront, reinforcing its mission to transform eyelid care and improve patients’ lives through its advanced technological offerings. The company aims to continue expanding its reach in the eyecare field, advocating for both patient access and physician support.
In conclusion, the establishment of Medicare reimbursement for the TearCare procedure represents a pivotal enhancement in the management of dry eye disease, reinforcing the critical role of innovative technologies in delivering better patient outcomes.
Comments